Filing Flows › Companies › X4 Pharmaceuticals › Report card
X4 Pharmaceuticals earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate5 of 5 reports beat the EPS estimate
X4 Pharmaceuticals (XFOR) beat the analysts' EPS estimate in 5 of its last 5 reports (100%), by +23.3% on average. On report days the stock moved 11.7% in either direction on median (largest 13.8%), rising 60% of the time; after a beat it rose 60% of the time.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported | Stock, the day | vs market |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Nov 4, 2026 | −$0.19 | −$0.16 | +14.0% | $2.8M | -3.2% | -0.3% |
| Q2 2026 | Aug 6, 2026 | −$0.18 | −$0.13 | +27.8% | $2.4M | +11.8% | +11.4% |
| Q1 2026 | May 6, 2026 | −$0.20 | −$0.16 | +20.0% | $2.5M | +2.1% | +1.1% |
| Q4 2025 | Mar 17, 2026 | −$0.35 | −$0.22 | +36.7% | $30.9M | +13.8% | +14.9% |
| Q3 2025 | Nov 5, 2025 | −$0.84 | −$0.69 | +18.2% | $1.6M | -11.7% | -11.0% |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.
Charts
The earnings-day move
Over 5 reports the stock moved 11.7% on median on the day (close to close), the largest move 13.8%.
After a beat the stock rose 60% of the time (5 beats).
The next report: what to expect → X4 Pharmaceuticals: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.